Flow chart of participant exclusions from the study.

<p>Definition of Poor Health Outcome at MESA Exam 5: Occurrence of death, cancer (excluding non-melanoma skin cancer),chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD; defined as myocardial infarction (MI), cardiac arrest, stroke, congestive heart failure (CHF), or peripheral vascular disease (PVD), cardiac revascularization, or definite angina), or presence of cognitive impairment or depression at MESA exam 5. Definition of Healthy: None of the above diseases/conditions.</p

Weighted Summary of Baseline Characteristics by Event for Participants with Poor Health Outcome at 10 Years of Follow Up in MESA.

<p>Weighted Summary of Baseline Characteristics by Event for Participants with Poor Health Outcome at 10 Years of Follow Up in MESA.</p

Weighted Multivariable Absolute Risk Regression for Poor Health Outcome At 10 Years of Follow Up in MESA.

<p>Weighted Multivariable Absolute Risk Regression for Poor Health Outcome At 10 Years of Follow Up in MESA.</p

Balance of Baseline Characteristics by Unknown Health Status at 10 Years of Follow Up in MESA Before and After Inverse Probability Weighting (IPW).

<p>Balance of Baseline Characteristics by Unknown Health Status at 10 Years of Follow Up in MESA Before and After Inverse Probability Weighting (IPW).</p

Weighted Summary and Bivariate Comparison of Baseline Characteristics by Health Outome Status at 10 Years of Follow Up in MESA.

<p>Weighted Summary and Bivariate Comparison of Baseline Characteristics by Health Outome Status at 10 Years of Follow Up in MESA.</p

Additional file 1: Figure S1. of Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study

Boxplot of left ventricular mass index (LVMI) and quartiles of systolic or diastolic blood pressures measured as predialysis 3-month average BP measurement stratified by ethnicity. Figure S2: Boxplot of left ventricular mass index (LVMI) and quartiles of systolic or diastolic blood pressures measured as prior to clinic BP measurement stratified by ethnicity. Figure S3: Boxplot of left ventricular mass index (LVMI) and quartiles of systolic or diastolic blood pressures measured as non-dialysis supine BP measurement stratified by ethnicity. Table S1: Independent associations of predialysis blood pressure, arterial, and volume measures with LVMI by linear regression among incident hemodialysis participants. Table S2: Independent associations of blood pressure prior to study visit, arterial, and volume measures withLVMI by linear regression among incident hemodialysis participants. Table S3: Independent associations of mean arterial pressure, arterial, and volume measures with LVMI by linear regression among incident hemodialysis participants. Table S4: Independent associations of pulse pressures, arterial, and volume measures with LVMI by linear regression among incident hemodialysis participants. Table S5: Association of preload and afterload measures with LVMI by linear regression among incident hemodialysis participants stratified by ethnicity. Table S6: Association of preload and afterload measures with LVMI by linear regression among incidenthemodialysis participants stratified by 3 month average IDWG groups. Table S7: Association of preload and afterload measures with LVMI by linear regression among incident hemodialysis participants stratified by β-blocker medication. Table S8: Association of preload and afterload measures with LVMI by linear regression among incident hemodialysis participants stratified by renin-angiotensin-aldosterone system (RAAS) blockade use. Table S9: Association of preload and afterload measures with LVMI by linear regression among incident hemodialysis participants stratified by history of congestive heart failure. Table S10: Association of hemoglobin with LVMI by linear regression among incident hemodialysis participants. (DOCX 97 kb

Mean difference in endothelial progenitor cells and circulating endothelial cells by COPD severity.

<p>Mean difference in endothelial progenitor cells and circulating endothelial cells by COPD severity.</p

Mean differences in endothelial progenitor cells and circulating endothelial cells according to the extent of emphysema and emphysema subtypes on radiologist interpretation.

<p>Mean differences in endothelial progenitor cells and circulating endothelial cells according to the extent of emphysema and emphysema subtypes on radiologist interpretation.</p

Clinical characteristics of participants in the MESA COPD Study with measures of endothelial progenitor cells, stratified by COPD severity.

<p>Clinical characteristics of participants in the MESA COPD Study with measures of endothelial progenitor cells, stratified by COPD severity.</p

Representation of EPCs levels with extent of emphysema on log-log scale by emphysema subtype.

<p>Lines represent modelling results after adjustment for age, gender, race/ethnicity, cohort, smoking status, pack-years, educational attainment, body mass index, height, diabetes mellitus, hypertension, oxygen saturation, white blood cell count, sleep apnea, HDL, and statin use. Panel A: CD34+KDR+. Panel B: CD34+KDR+CD133+. PLE is panlobular emphysema, CLE is centrilobular emphysema and PSE is paraseptal emphysema.</p